Association of Barrett’s esophagus with Helicobacter pylori infection: a meta-analysis

Abstract

Background and Aims:

Barrett’s esophagus (BE) is the only recognized precursor for esophageal adenocarcinoma. Helicobacter pylori (H. pylori) infection is a major contributing factor towards upper gastrointestinal diseases, but its relationship with BE remains controversial. Some previous studies suggested that H. pylori infection negatively correlated with BE, while others did not. This may be attributed to the difference in the selection of control groups among studies. The present meta-analysis aims to clarify their association by combining all available data from well-designed studies.

Methods:

The PubMed, EMBASE, and Cochrane Library databases were searched. Odds ratios (ORs) with 95% confidence intervals (CIs) were pooled by a random-effects model. Heterogeneity was evaluated using the Cochran’s Q test and I² statistics. Meta-regression, subgroup, and leave-one-out sensitivity analyses were employed to explore the sources of heterogeneity.

Results:

Twenty-four studies with 1,354,369 participants were included. Meta-analysis found that patients with BE had a significantly lower prevalence of H. pylori infection than those without (OR = 0.53, 95% CI = 0.45–0.64; p < 0.001). The heterogeneity was statistically significant (I² = 79%; p < 0.001). Meta-regression, subgroup, and leave-one-out sensitivity analyses did not find any source of heterogeneity. Meta-analysis of 7 studies demonstrated that CagA-positive H. pylori infection inversely correlated with BE (OR = 0.25, 95% CI = 0.15–0.44; p = 0.000), but not CagA-negative H. pylori infection (OR = 1.22, 95% CI = 0.90–1.67; p = 0.206). Meta-analysis of 4 studies also demonstrated that H. pylori infection inversely correlated with LSBE (OR = 0.39, 95% CI = 0.18–0.86; p = 0.019), but not SSBE (OR = 0.73, 95% CI = 0.30–1.77; p = 0.484).

Conclusion:

H. pylori infection negatively correlates with BE. More experimental studies should be necessary to elucidate the potential mechanisms in future.

Keywords

Barrett’s esophagus esophageal adenocarcinoma gastroesophageal reflux disease meta-analysis

Introduction

Barrett’s esophagus (BE), a precancerous lesion of esophageal adenocarcinoma (EAC), is defined as the squamous epithelium replaced by specialized intestinal metaplasia (IM).¹ It is often asymptomatic and can only be diagnosed by endoscopy.² Risk factors of BE include age greater than 50 years, male, smoking, white race, gastroesophageal reflux disease (GERD), high body mass index (BMI), and hiatal hernia.³ Its prevalence is approximately 10% to 15% in patients with GERD.^4,5

Helicobacter pylori (H. pylori), a gram-negative microaerophilic bacterium, influences at least 50% of the world’s population.⁶ At present, H. pylori is the most common causative agent of infection-associated cancers, accounting for 5.5% of the global cancer burden.⁷ The importance of H. pylori in upper gastrointestinal pathology is undoubted, because it can lead to gastric and duodenal ulcers, mucosa-associated tissue lymphoma, non-Hodgkin’s lymphoma of the stomach, and gastric adenocarcinoma.⁸ Nevertheless, the relationship between H. pylori and esophagus diseases, especially BE, remains controversial.⁹ Some studies have reported that H. pylori is a risk factor for BE,^10,11 while others have inferred that H. pylori has a protective effect on BE^12,13 and that H. pylori infection may not be associated with BE.^14,15 Until now, several meta-analyses have explored their association. However, among these meta-analyses, not all control subjects have undergone endoscopy, which may cause missed diagnoses of GERD or peptic ulcer, thereby overestimating or underestimating the effect of H. pylori infection on BE. Therefore, we have comprehensively collected the most recent data from well-designed studies and conducted a meta-analysis to analyze the correlation between H. pylori and BE.

Methods

The meta-analysis was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The PRISMA checklist is shown in Supplementary Material .

Registration

The meta-analysis was registered in PROSPERO with a registration number of CRD42021241042.

Literature search

All relevant papers regarding the prevalence of H. pylori infection in patients with and without BE were searched in the PubMed, EMBASE, and Cochrane Library databases. The search was performed using the following terms: (‘Helicobacter pylori’ OR ‘H pylori’ OR ‘H. pylori’ OR ‘Helicobacter’ OR ‘Campylobacter Pylori’) AND (‘Barrett esophagus’ OR ‘Barrett’ OR ‘Barrett metaplasia’ OR ‘Barrett oesophagus’). The last search was conducted on November 11, 2021. There was no language restriction.

Selection criteria

Inclusion criteria were as follows: (1) observational (case-control or cross-sectional) studies, (2) all participants should undergo upper gastrointestinal endoscopy, (3) studies should compare the prevalence of H. pylori infection between participants with and without BE, and (4) H. pylori infection should be confirmed by histology, rapid urease test, culture, stool antigen test, and/or serology.

Exclusion criteria were as follows: (1) duplicated studies; (2) reviews and meta-analyses; (3) case reports; (4) guidelines, consensus, or reports; (5) editorials, comments, letters, or notes; (6) experimental or animal studies; (7) studies which did not explore the association between H. pylori infection and BE; (8) participants had peptic ulcer or gastric cancer; (9) participants in control groups did not undergo upper gastrointestinal endoscopy; (10) participants in control groups had GERD; (11) overlapping participants among studies; and (12) absence of relevant data.

Data extraction

The following data were extracted from the included studies: first author, publication year, country, study design, number of participants in case and control groups, the prevalence of H. pylori infection in the 2 groups, methods and biopsy sites for detecting H. pylori infection, diagnostic criteria for BE, diagnostic timing of BE, whether age and gender were matched between participants with and without BE, whether participants with a history of H. pylori eradication therapy were excluded, whether participants who used proton pump inhibitors (PPIs) within at least 2 weeks before detection of H. pylori infection were excluded, and the prevalence of H. pylori infection according to the segment lengths of BE and status of cytotoxin-associated gene A (CagA).

Study quality assessment

The quality of included case-control studies was assessed by the Newcastle-Ottawa Scale (NOS), which includes study selection (4 points), comparability (2 points), and exposure (3 points). The maximum NOS score is 9. A score of 0–3, 4–6, and 7–9 represents low, moderate, and high quality, respectively.

The quality of included cross-sectional studies was assessed with 11 items formulated by the Agency for Healthcare Research and Quality (AHRQ), which are answered with "yes", "no", or "unclear". The maximum AHRQ score is 11. A score of 0–3, 4–7, and 8–11 represents low, moderate, and high quality, respectively.

Statistical analyses

All statistical analyses were performed using Review Manager software (Version 5.4, Cochrane collaboration, the Nordic Cochrane Center, Copenhagen, Denmark) and Stata software (Version 12.0, Stata Corp, College Station, USA). We pooled the odds ratios (ORs) and 95% confidence intervals (CIs) by using a random-effects model. Forest plots were constructed for a visual display of ORs of individual studies. The Cochrane Q test and I² statistics were employed to assess the heterogeneity. I² > 50% and/or p < 0.1 were considered to have statistically significant heterogeneity. Leave-one-out sensitivity analyses were assessed by sequentially omitting 1 study each time. Subgroup analyses were performed according to study design (case-control vs cross-sectional), publication year (before 2010 vs after 2010), region (Asia vs Europe vs America), country (Eastern vs Western), methods for detecting H. pylori (histology/rapid urease test vs serology vs ⩾ 2 diagnostic methods), sample size (<10,000 vs >10,000), number of biopsy sites for detecting H. Pylori (1 vs ⩾ 2), diagnostic criteria for BE (IM vs CM), diagnostic timing of BE (newly vs previously diagnosed), whether age and gender were matched between patients with and without BE (matched vs unmatched), participants with a history of H. pylori eradication therapy (excluded vs not excluded), and participants who used PPIs within at least 2 weeks before detection of H. pylori infection (excluded vs not excluded). The interaction between subgroups was tested. Meta-regression analyses were also employed according to the variables mentioned above. Publication bias among the included studies was checked by the Egger test. p < 0.1 was considered as a statistically significant publication bias. In addition, the prevalence of H. pylori infection according to different segment lengths of BE (LSBE vs SSBE) and status of CagA (CagA-positive vs CagA-negative) were also compared.

Results

Study selection

Our initial search identified 2,422 studies from the PubMed, EMBASE, and Cochrane Library databases, and 1 study from hand-searching. Finally, 24 studies with 1,354,369 participants were included (Figure 1). Notably, 2 of them had overlapping participants, but explored different variables. One had a larger sample size, but just provided the data in LSBE participants;¹⁶ and the other had a smaller sample size, but specifically compared the prevalence of H. pylori infection according to different segment lengths of BE.¹⁷

Figure 1.

A flowchart of study inclusion.

Study characteristics

Characteristics of the included studies were shown in Table 1. Among them, 14 studies were case-control studies, and 9 were cross-sectional studies. They were published between 1988 and 2020. Five studies were performed in Asia,^{16,19,22,25,27} 11 in Europe,^{20,23,26,28–30,32–34,36,37} and 7 in America.^{12,18,21,24,31,35,38}

Table 1.

Summary of baseline characteristics of the prevalence of H. pylori infection in patients with and without BE.

First author	Country	Studydesign	BE on endoscopy		Prevalence ofH. pylori infection		Methods for detection of H. pylori	Biopsy sites for detecting H. pylori	Diagnostic criteria for BE	Diagnostic timing of BE	Age and gender matched between 2 groups	Exclusion criteria for participants
First author	Country	Studydesign	BE	No BE	BE	No BE	Methods for detection of H. pylori	Biopsy sites for detecting H. pylori	Diagnostic criteria for BE	Diagnostic timing of BE	Age and gender matched between 2 groups	History of H. pylori eradication therapy	Using PPIs within at least 2 weeks before detection of H. pylori infection
Turner et al.¹⁸	USA	Cross-sectional	52186	1207207	2332/ 52186	126351/ 1207207	H	Antral, corpus, and angus	IM	NA	No	No	No
Zhang et al.¹⁹	China	Case-control	40	40	15/40	23/40	H, R	Esophageal and antral	CM	NA	No	No	No
Xu et al.²⁰	UK	Cross-sectional	38	202	3/38	34/202	R, S	NA	IM	NA	No	No	No
Tan et al.²¹	USA	Cross-sectional	329	1856	68/329	606/ 1856	H	Antral, corpus, and cardia	IM	Previously	No	No	No
Chen et al.²²	China	Case-control	161	644	42/148	261/588	R	Antral	IM	NA	Yes	No	Yes
Dore et al.²³	Italy	Cross-sectional	133	1772	49/131	669/ 1772	H, R, U	Antral and corpus	IM	Newly	No	No	Yes
Rubenstein et al.¹²	USA	Case-control	150	177	25/150	46/177	S	NA	IM	Newly	No	No	No
Sonnenberg et al.²⁴	USA	Cross-sectional	2510	76475	144/ 2510	9356/ 76475	H	Antral, corpus, and angus	IM	Previously	No	No	No
Abe et al.¹⁶	Japan	Case-control	36	108	4/36	80/108	H, S, R	Antral, corpus	CM	Newly	Yes	Yes	Yes
Rajendra et al.²⁵	Malaysia	Case-control	55	53	29/55	32/53	H, S, R	Antral, corpus, and cardia	IM	Previously	No	Yes	Yes
^§lnomata et al.¹⁷	Japan	Case-control	36	80	3/36	57/80	H, S, R	Antral, corpus	IM	NA	No	Yes	Yes
Loffeld et al.²⁶	Netherlands	Cross-sectional	307	5341	55/179	1550/ 3975	H, C	Antral	NA	Previously	No	No	No
Rajendra et al.²⁷	Malaysia	Case-control	123	1741	46/123	604/ 1741	H, R	Antral and corpus	IM	NA	No	Yes	Yes
Ackermark et al.²⁸	Netherlands	Cross-sectional	51	62	21/51	39/62	S	NA	IM	NA	No	No	No
Laheij et al.²⁹	Netherlands	Cross-sectional	23	528	6/23	281/528	H, C, R	Antral and corpus	CM	NA	No	Yes	No
Rugge et al.³⁰	Italy	Case-control	53	53	19/53	36/53	H, S, P	Antral, corpus, and incisural	IM	NA	Yes	Yes	Yes
Vaezi et al.³¹	USA	Case-control	83	60	28/83	25/60	H, S	Antral, corpus	CM	Previously	No	Yes	No
Loffeld et al.³²	Netherlands	Cross-sectional	36	454	14/36	248/454	H, S, R, C	Antral	CM	Newly	No	Yes	Yes
Vieth et al.³³	Germany	Case-control	1054	712	562/ 1054	468/712	H	Antral and corpus	IM	Previously	No	No	No
Kiltz et al.³⁴	Germany	Case-control	35	320	8/35	91/320	R, S	Antrum and corpus	CM	Previously	No	Yes	No
Vicari et al.³⁵	USA	Case-control	48	57	15/48	26/57	H, S	Antral, fundus, and cardia	CM	Previously	No	No	No
Werdmuller et al.³⁶	Netherlands	Case-control	13	399	3/13	204/399	H, R, C, S	Antral	NA	NA	No	No	No
Newton et al.³⁷	UK	Case-control	16	25	4/16	9/25	H, R	Antral and fundus	CM	Previously	No	No	Yes
Paull et al.³⁸	USA	Case-control	26	26	10/26	11/26	H	Gastric and esophageal	CM	Previously	Yes	No	No

Study only in the analysis for BE segment length.

BE, Barrett’s esophagus; C, culture; CM, columnar metaplasia; H, histology; IM, intestinal metaplasia; PCR, polymerase chain reaction; PPIs, proton pump inhibitors; S, serology; SA, stool antigen; R, rapid urease test; U, urea breath test.

Study quality

Among the case-control studies, 8 and 6 were of moderate and high quality, respectively (Supplementary Table 1). Among the cross-sectional studies, 3 and 6 were of moderate and high quality, respectively (Supplementary Table 2).

Meta-analyses in overall patients

Meta-analysis demonstrated a significantly lower prevalence of H. pylori infection in patients with BE than those without (OR = 0.53, 95% CI = 0.45–0.64; p < 0.001). The heterogeneity was statistically significant (I²=79%; p < 0.001) (Figure 2).

Figure 2.

Forest plots showing the association of H. pylori infection with BE.

Results of sensitivity analyses were shown in Supplementary Table 3. After omitting each study, the heterogeneity remained statistically significant.

Results of subgroup analyses were shown in Table 2. Regardless of study design, publication year, region, country, diagnostic methods of H. pylori infection, sample size, number of biopsy sites for detecting H. pylori, diagnostic criteria for BE, diagnostic timing of BE, age and gender matched between 2 groups, participants with a history of H. pylori eradication therapy, and participants who used PPIs within at least 2 weeks before detection of H. pylori infection, meta-analyses demonstrated a significantly lower prevalence of H. pylori infection in patients with BE than those without. The interaction between subgroups was only significant in the subgroup analysis according to the sample size (p = 0.002), but not in others.

Table 2.

Results of subgroup analyses regarding the association of H. pylori infection with BE.

Groups	No.Studies	OR (95%CI)	Heterogeneity		P_interaction
Groups	No.Studies	OR (95%CI)	I² (%)	p value	P_interaction
Total	23	0.53 (0.45-0.64; p < 0.001)	79%	<0.001
Study design					0.940
Case-control	14	0.53 (0.39–0.71; p < 0.001)	67%	<0.001
Cross-sectional	9	0.52 (0.42–0.65; p < 0.001)	79%	<0.001
Publication year					0.870
After 2010	8	0.51 (0.42–0.63; p < 0.001)	76%	<0.001
Before 2010	15	0.53 (0.40–0.70; p < 0.001)	66%	<0.001
Region					0.220
Asia	5	0.43 (0.20–0.93; p = 0.030)	88%	<0.001
Europe	11	0.58 (0.46–0.73; p < 0.001)	39%	0.090
America	7	0.46 (0.40–0.53; p < 0.001)	46%	0.080
Country					0.580
Eastern	5	0.43 (0.20–0.93; p = 0.030)	88%	<0.001
Western	18	0.54 (0.45–0.64; p < 0.001)	72%	<0.001
Diagnostic methods of H. Pylori					0.900
Histology/RUT	6	0.48 (0.41–0.58; p < 0.001)	77%	<0.001
Serology	3	0.50 (0.33–0.76; p = 0.001)	0%	0.770
⩾ 2 diagnostic methods	14	0.53 (0.38–0.74; p < 0.001)	71%	<0.001
Sample size					0.002
> 10000	2	0.40 (0.39–0.42; p < 0.001)	0%	0.330
< 10000	21	0.56 (0.46–0.68; p < 0.001)	61%	<0.001
Number of biopsy sites for detecting H. Pylori					0.610
1	4	0.58 (0.46–0.73; p < 0.001)	0%	0.400
⩾ 2	16	0.54 (0.43–0.67; p < 0.001)	84%	<0.001
Diagnostic criteria for BE					0.410
IM	12	0.56 (0.45–0.69; p < 0.001)	85%	<0.001
CM	9	0.44 (0.27–0.73; p = 0.001)	64%	0.005
Diagnostic timing of BE					0.450
Newly diagnosed	4	0.39 (0.15–0.98; p < 0.001)	89%	<0.001
Previously diagnosed	11	0.55 (0.48–0.63; p < 0.001)	17%	0.280
Age and gender matched between 2 groups					0.160
Matched	4	0.28 (0.10–0.76; p < 0.001)	84%	<0.001
Unmatched	19	0.58 (0.48–0.69; p < 0.001)	79%	<0.001
Participants with a history of H. pylori eradication therapy					0.570
Excluded	8	0.45 (0.25–0.81; p = 0.008)	82%	<0.001
Not excluded	15	0.54 (0.45–0.64; p < 0.001)	75%	<0.001
Participants who used PPIs within at least 2 weeks before detection of H. pylori infection					0.910
Excluded	8	0.50 (0.29–0.83; p = 0.008)	83%	<0.001
Not excluded	15	0.51 (0.44–0.60; p < 0.001)	63%	<0.001

BE, Barrett’s esophagus; CM, columnar metaplasia; IM, intestinal metaplasia; OR, odds ratio; PPIs, proton pump inhibitors; RUT, rapid urease test.

Meta-regression analyses did not find any source of heterogeneity (Supplementary Table 4). Egger test showed significant evidence of publication bias (p = 0.043).

Meta-analyses regarding association of CagA status with BE

Seven studies compared the prevalence of H. pylori infection according to different status of CagA (Supplementary Table 5). There was a significantly lower prevalence of CagA-positive H. pylori infection in patients with BE than those without BE (OR = 0.25, 95% CI = 0.15–0.44; p = 0.000). The heterogeneity was not statistically significant (I² = 42%; P = 0.111) (Supplementary Figure 1). By contrast, the prevalence of CagA-negative H. pylori infection was statistically similar between patients with and without BE (OR = 1.22, 95% CI = 0.90–1.67; p = 0.206). The heterogeneity was not statistically significant (I² = 0%; p = 0.881) (Supplementary Figure 2).

Meta-analyses regarding association of H. pylori with BE segment lengths

Four studies compared the prevalence of H. pylori infection according to different segment lengths of BE (Supplementary Table 6). There was a significantly lower prevalence of H. pylori infection in patients with LSBE than those without BE (OR = 0.39, 95% CI = 0.18–0.86; p = 0.019). The heterogeneity was statistically significant (I² = 66%; p = 0.033) (Supplementary Figure 3). By contrast, the prevalence of H. pylori infection was statistically similar between patients with SSBE and those without BE (OR = 0.73, 95% CI = 0.30–1.77; p = 0.484). The heterogeneity was statistically significant (I² = 76%; p = 0.005) (Supplementary Figure 4). It is inappropriate to conduct meta-regression analyses to explore the sources of heterogeneity since only 4 studies were included.³⁹

Discussion

This is an updated meta-analysis which more comprehensively searched relevant studies to explore the relationship between H. pylori infection and BE. Our study found that the prevalence of H. pylori infection was significantly lower in patients with BE than those without, suggesting that H. pylori infection is inversely related to BE.

Seven previous meta-analyses were performed to explore the relationship between H. pylori infection and BE. However, their conclusions were inconsistent. The meta-analysis by Wang et al.⁴⁰ demonstrated no association of H. pylori infection with BE; by comparison, 6 others reported a significantly lower prevalence of H. pylori infection in patients with BE than those without.^41–46

Our current meta-analysis has several advantages as compared to previous ones. First, there was a more comprehensive collection of eligible studies by expanding the search strategy and updating the final search date. Second, a larger number of subgroup analyses were planned to further explore the association between H. pylori infection and BE according to the 12 prespecified co-variates. More importantly, the interaction between subgroups was also tested to infer whether the protective effect of H. pylori infection on BE differs among subgroups, which has not been performed in 7 previous meta-analyses yet. Third, meta-regression analyses, an important statistical method for analyzing the source of heterogeneity, were performed in our meta-analysis, but have not been done in previous meta-analyses yet. Fourth, the selection of eligible participants in our meta-analysis is more reasonable and rigorous. In details, all participants included should have undergone upper gastrointestinal endoscopy; all participants included should not have been diagnosed with gastric cancer or peptic ulcer; and the participants included in control groups should not have been diagnosed with GERD. Such considerations are very important to eliminate the effects of these potential confounding factors on the reliability of our findings. By comparison, these selection criteria have not been employed by previous meta-analyses yet. More importantly, a remarkable negative correlation between H. pylori infection and BE has been observed in all of our subgroup analyses, strengthening the robustness of our conclusion.

Currently, the pathogenesis of BE is primarily attributed to frequently transient lower esophageal sphincter (LES) relaxation, which leads to gastric acid reflux, resulting in esophageal mucosa injury.^47,48 The protective effect of H. pylori infection on BE may be explained by its secondary reduction in gastric acid secretion and reflux.

First, there are several possible mechanisms that H. pylori infection protects against BE by reducing gastric acid secretion, as follows: (1) fatty acids produced by H. pylori can directly inhibit parietal cell function, and then reduce gastric acid secretion;⁴⁹ (2) cytokines, such as TNF-α and IL-1ß, resulting from corpus-predominant gastritis caused by H. pylori infection, can also inhibit parietal cell function, thereby reducing gastric acid secretion;^50,51 (3) long-term colonization of H. pylori in stomach can cause atrophic gastritis, which reduces the number of parietal cell, further decreasing gastric acid secretion; and (4) ghrelin can protect gastric mucosa⁵² and promote gastric acid secretion.⁵³ H. pylori infection causes corpus gastritis and/or gastric atrophic changes,^54,55 leading to the loss of ghrelin producing cells and reduction of plasma ghrelin concentrations, which finally aggravates gastric mucosal damage and reduces gastric acid secretion.

Second, there are some potential mechanisms that H. pylori infection protects against BE by reducing gastric acid reflux, as follows: (1) elevated serum gastrin levels in antrum-predominant H. pylori gastritis may increase LES pressure, and then reduce gastric acid reflux;⁵⁶ and (2) ghrelin may promote food intake.⁵⁷ A decreased level of ghrelin secondary to H. pylori infection is associated with a reduction of BMI with a lower intra-abdominal pressure which decreases gastric acid reflux.⁵⁸ In addition, bile acids in combination with low pH may induce oxidative stress and DNA damage in esophageal cells, resulting in the activation of anti-apoptotic pathways and increased inflammatory response on esophageal tissues.⁵⁹ By contrast, reduced bile acids reflux, which can result from increased LES pressure and decreased intra-abdominal pressure caused by H. pylori infection, may play an important role in the protective effect on BE.^60–63

Third, H. pylori DNA may directly down-regulate the inflammatory stimulation of type 1 interferon and IL-12 on esophageal mucosa, and then delay the progression of BE.^64,65

Our meta-analysis demonstrated a significant association of BE with CagA-positive H. pylori infection, but not CagA-negative H. pylori infection. CagA can encode a high-molecular-weight immunodominant antigen that can induce IL-8 production.^66–68 CagA-positive strains are also associated with enhanced local inflammatory response.^69,70 Hence, CagA-positive H. pylori infection induces more severe gastric inflammation and multifocal atrophic gastritis, finally resulting in a reduction of gastric acid secretion.^71,72

Our meta-analysis also found a significant association of H. pylori infection with LSBE, but not SSBE. Unfortunately, there is no direct evidence used to explain this phenomenon. It seems obvious that SSBE has a lower degree of gastric acid exposure than LSBE.^73,74 Accordingly, it is hypothesized that SSBE may be less affected by a reduction of gastric acid secretion and reflux attributed to H. pylori infection compared with LSBE. It should be acknowledged that only 4 small studies explored the prevalence of H. pylori infection according to different segment lengths of BE. Thus, such statistical results may be unpowered.

Our meta-analysis had several other limitations. First, most of the included studies were retrospective, leading to the selection bias and recall bias. Second, the heterogeneity among studies was significant, in spite of leave-one-out sensitivity and meta-regression analyses. Third, 2 studies^29,37 performed biopsies at different sites to assess H. pylori infection and provided more than 1 H. pylori infection rate. Only the H. pylori infection in the antrum was selected for the present meta-analysis, which may underestimate the prevalence of H. pylori infection.^75,76 Forth, the absence of detailed information on race or ethnicity may compromise from estimating the prevalence of H. pylori infection in different racial or ethnic groups of BE patients. Fifth, the definitions of BE proposed by current practice guidelines and consensus are different among countries. IM is a required criterion for BE according to the American College of Gastroenterology clinical guideline published 2016,⁷⁷ but not the Chinese consensus published 2017.⁷⁸ Considering that currently available data regarding association of H. pylori with BE are from West, more well-designed studies should be conducted in China.

Our findings indicate an inverse relationship between H. pylori infection and BE. Accordingly, it appears that H. pylori eradication is not beneficial for the prevention of BE, which is contrary to the recommendations of current practice guidelines and consensus regarding management of H. pylori infection.⁶ Indeed, other evidence also suggest the benefits of H. pylori infection on decreasing the risk of EAC,⁷⁹ especially Barrett’s adenocarcinoma,⁸⁰ and allergic diseases.⁸¹ Therefore, we should re-evaluate the necessity of eliminating this pathogen globally, especially in the West, where gastric adenocarcinoma and peptic ulcer disease are much less prevalent.

Conclusion

The current study suggests that H. pylori infection is inversely related to BE. More well-designed prospective cohort studies are required to confirm our findings in future, and experimental studies should also be necessary to elucidate the potential mechanisms.

Supplemental Material

sj-docx-1-taj-10.1177_20406223221117971 – Supplemental material for Association of Barrett’s esophagus with Helicobacter pylori infection: a meta-analysis

Supplemental material, sj-docx-1-taj-10.1177_20406223221117971 for Association of Barrett’s esophagus with Helicobacter pylori infection: a meta-analysis by Shaoze Ma, Xiaozhong Guo, Chunmei Wang, Yue Yin, Guangqin Xu, Hongxin Chen and Xingshun Qi in Therapeutic Advances in Chronic Disease

Footnotes

Acknowledgements

None.

Abbreviations

BE, Barrett’s esophagus; EAC, esophageal adenocarcinoma; GERD, gastroesophageal reflux disease; BMI, body mass index; H. pylori, Helicobacter pylori; PPIs, proton pump inhibitors; CagA, cytotoxin-associated gene A; NOS, Newcastle-Ottawa Scale; AHRQ, Agency for Healthcare Research and Quality; ORs, odds ratios; CIs, confidence intervals; CM, columnar metaplasia; IM, intestinal metaplasia; LES, lower esophageal sphincter; TNF, tumor necrosis factor; IL, interleukin.

Declarations

ORCID iD

Xingshun Qi

Supplemental material

Supplemental material for this article is available online.

References

Fitzgerald

di Pietro

Ragunath

, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014; 63: 7–42.

Kuipers

Spaander

MC.

Natural history of Barrett’s esophagus. Dig Dis Sci 2018; 63: 1997–2004.

Qumseya

Bukannan

Gendy

, et al. Systematic review and meta-analysis of prevalence and risk factors for Barrett’s esophagus. Gastrointest Endosc 2019; 90: 707–717.

Sharma

Clinical practice. Barrett’s Esophagus. N Engl J Med 2009; 361: 2548–2556.

Badreddine

Wang

KK.

Barrett’s esophagus: pathogenesis, treatment, and prevention. Gastrointest Endosc Clin N Am 2008; 18: 495–512ix.

Malfertheiner

Megraud

O’Morain

, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6–30.

Noto

Peek

Jr.

Helicobacter pylori: an overview. Methods Mol Biol 2012; 921: 7–10.

Pohl

Keller

Bordier

, et al. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World J Gastroenterol 2019; 25: 4629–4660.

Boltin

Niv

Schütte

, et al. Review: helicobacter pylori and non-malignant upper gastrointestinal diseases. Helicobacter 2019; 24(Suppl. 1): e12637.

10.

Ferrández

Benito

Arenas

, et al. CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett’s esophagus in a population with high H. Pylori Infection Rate. BMC Gastroenterol 2006; 6: 7.

11.

Henihan

Stuart

Nolan

, et al. Barrett’s esophagus and the presence of Helicobacter pylori. Am J Gastroenterol 1998; 93: 542–546.

12.

Rubenstein

Inadomi

Scheiman

, et al. Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol 2014; 12: 239–245.

13.

Corley

Kubo

Levin

, et al. Helicobacter pylori infection and the risk of Barrett’s oesophagus: a community-based study. Gut 2008; 57: 727–733.

14.

Peng

Cui

Xiao

, et al. Prevalence of erosive esophagitis and Barrett’s esophagus in the adult Chinese population. Endoscopy 2009; 41: 1011–1017.

15.

Abbas

Hussainy

Ibrahim

, et al. Barrett’s oesophagus and Helicobacter pylori. J Gastroenterol Hepatol 1995; 10: 331–333.

16.

Abe

Iijima

Koike

, et al. Barrett’s esophagus is characterized by the absence of Helicobacter pylori infection and high levels of serum pepsinogen I concentration in Japan. J Gastroenterol Hepatol 2009; 24: 129–134.

17.

Inomata

Koike

Ohara

, et al. Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. Am J Gastroenterol 2006; 101: 926–933.

18.

Turner

Genta

Sonnenberg

The meaning of incidental goblet cells at the gastroesophageal junction. Dig Dis Sci 2021; 66: 1588–1592.

19.

Zhang

Tan

Sun

, et al. Experimental study of the effect of helicobacter pylori infection on barrett esophagus and its correlation with immune function. Jundishapur Journal of Microbiology 2020; 13: 1–6.

20.

Miremadi

Link

, et al. Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study. J Clin Pathol 2019; 72: 825–829.

21.

Tan

Murrey-Ittmann

Nguyen

, et al. Risk profiles for Barrett’s esophagus differ between new and prevalent, and long- and short-segment cases. PLoS ONE 2016; 11: e0169250.

22.

Chen

Hsu

Lee

, et al. Central obesity and H. pylori infection influence risk of Barrett’s esophagus in an Asian population. PLoS ONE 2016; 11: e0167815.

23.

Dore

Pes

Bassotti

, et al. Risk factors for erosive and non-erosive gastroesophageal reflux disease and Barrett’s esophagus in Nothern Sardinia. Scand J Gastroenterol 2016; 51: 1281–1287.

24.

Sonnenberg

Lash

Genta

RM.

A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 2010; 139: 1894–1901.

25.

Rajendra

Ackroyd

Robertson

, et al. Helicobacter pylori, ethnicity, and the gastroesophageal reflux disease spectrum: a study from the East. Helicobacter 2007; 12: 177–183.

26.

Loffeld

van der Putten

AB.

Helicobacter pylori and gastro-oesophageal reflux disease: a cross-sectional epidemiological study. Neth J Med 2004; 62: 188–191.

27.

Rajendra

Kutty

Karim

Ethnic differences in the prevalence of endoscopic esophagitis and Barrett’s esophagus: the long and short of it all. Dig Dis Sci 2004; 49: 237–242.

28.

Ackermark

Kuipers

Wolf

, et al. Colonization with cagA-positive Helicobacter pylori strains in intestinal metaplasia of the esophagus and the esophagogastric junction. Am J Gastroenterol 2003; 98: 1719–1724.

29.

Laheij

Van Rossum

De Boer

, et al. Corpus gastritis in patients with endoscopic diagnosis of reflux oesophagitis and Barrett’s oesophagus. Aliment Pharmacol Ther 2002; 16: 887–891.

30.

Rugge

Russo

Busatto

, et al. The phenotype of gastric mucosa coexisting with Barrett’s oesophagus. J Clin Pathol 2001; 54: 456–460.

31.

Vaezi

Falk

Peek

, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett’s esophagus. Am J Gastroenterol 2000; 95: 2206–2211.

32.

Loffeld

Werdmuller

Kuster

, et al. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett’s esophagus. Digestion 2000; 62: 95–99.

33.

Vieth

Masoud

Meining

, et al. Helicobacter pylori infection: protection against Barrett’s mucosa and neoplasia. Digestion 2000; 62: 225–231.

34.

Kiltz

Baier

Schmidt

, et al. Barrett’s metaplasia and Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 1985–1986.

35.

Vicari

Peek

Falk

, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50–57.

36.

Werdmuller

Loffeld

RJ.

Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997; 42: 103–105.

37.

Newton

Bryan

Burnham

, et al. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett’s oesophagus. Gut 1997; 40: 9–13.

38.

Paull

Yardley

JH.

Gastric and esophageal Campylobacter pylori in patients with Barrett’s esophagus. Gastroenterology 1988; 95: 216–218.

39.

Higgins

Thompson

Deeks

, et al. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J Health Serv Res Policy 2002; 7: 51–61.

40.

Wang

Yuan

Hunt

RH.

Helicobacter pylori infection and Barrett’s esophagus: a systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 492–500; quiz 491–501.

41.

Gisbert

Pajares

JM.

[Prevalence of Helicobacter pylori infection in gastroesophageal reflux disease and Barrett’s esophagus]. Med Clin (Barc) 2002; 119: 217–223.

42.

Rokkas

Pistiolas

Sechopoulos

, et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1413–71417.

43.

Fischbach

Nordenstedt

Kramer

, et al. The association between Barrett’s esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter 2012; 17: 163–175.

44.

Erőss

Farkas

Vincze

, et al. Helicobacter pylori infection reduces the risk of Barrett’s esophagus: a meta-analysis and systematic review. Helicobacter 2018; 23: e12504.

45.

Wang

Shaheen

Whiteman

, et al. Helicobacter pylori infection is associated with reduced risk of Barrett’s esophagus: an analysis of the Barrett’s and esophageal adenocarcinoma consortium. Am J Gastroenterol 2018; 113: 1148–1155.

46.

Duan

LP.

Helicobacter pylori infection is associated with reduced risk of Barrett’s esophagus: a meta-analysis and systematic review. BMC Gastroenterol 2021; 21: 459.

47.

Steele

Baig

KKK

Peter

Evolving screening and surveillance techniques for Barrett’s esophagus. World J Gastroenterol 2019; 25: 2045–2057.

48.

Kahrilas

PJ.

GERD pathogenesis, pathophysiology, and clinical manifestations. Cleve Clin J Med 2003; 70(Suppl. 5): S4–S19.

49.

Beil

Birkholz

Wagner

, et al. Interaction of Helicobacter pylori and its fatty acids with parietal cells and gastric H+/K(+)-ATPase. Gut 1994; 35: 1176–1180.

50.

Hackelsberger

Günther

Schultze

, et al. Role of aging in the expression of Helicobacter pylori gastritis in the antrum, corpus, and cardia. Scand J Gastroenterol 1999; 34: 138–143.

51.

Beales

Calam

Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 1998; 42: 227–234.

52.

Sibilia

Rindi

Pagani

, et al. Ghrelin protects against ethanol-induced gastric ulcers in rats: studies on the mechanisms of action. Endocrinology 2003; 144: 353–359.

53.

Date

Nakazato

Murakami

, et al. Ghrelin acts in the central nervous system to stimulate gastric acid secretion. Biochem Biophys Res Commun 2001; 280: 904–907.

54.

Osawa

Ghrelin and Helicobacter pylori infection. World J Gastroenterol 2008; 14: 6327–6333.

55.

Tatsuguchi

Miyake

Gudis

, et al. Effect of Helicobacter pylori infection on ghrelin expression in human gastric mucosa. Am J Gastroenterol 2004; 99: 2121–2127.

56.

Kandulski

Malfertheiner

Helicobacter pylori and gastroesophageal reflux disease. Curr Opin Gastroenterol 2014; 30: 402–407.

57.

Nakazato

Murakami

Date

, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194–198.

58.

Corley

Kubo

Levin

, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology 2007; 133: 34–41; quiz 311.

59.

Dvorak

Payne

Chavarria

, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett’s oesophagus. Gut 2007; 56: 763–771.

60.

Pfaffenbach

Hullerum

Orth

, et al. Bile and acid reflux in long and short segment Barrett’s esophagus, and in reflux disease. Z Gastroenterol 2000; 38: 565–570.

61.

Richter

Do we know the cause of reflux disease. Eur J Gastroenterol Hepatol 1999; 11(Suppl. 1): S3–S9.

62.

Castell

Murray

Tutuian

, et al. Review article: the pathophysiology of gastro–oesophageal reflux disease – oesophageal manifestations. Aliment Pharmacol Ther 2004; 20(Suppl. 9): 14–25.

63.

Bozymski

EM.

Pathophysiology and diagnosis of gastroesophageal reflux disease. Am J Hosp Pharm 1993; 50(4 Suppl. 1): S4–S6.

64.

Luther

Owyang

Takeuchi

, et al. Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis. Gut 2011; 60: 1479–1486.

65.

Moons

Kusters

van Delft

, et al. A pro-inflammatory genotype predisposes to Barrett’s esophagus. Carcinogenesis 2008; 29: 926–931.

66.

Tohidpour

CagA-mediated pathogenesis of Helicobacter pylori. Microb Pathog 2016; 93: 44–55.

67.

Zeng

Chen

, et al. N-terminal region of Helicobacter pylori CagA induces IL-8 production in gastric epithelial cells via the β1 integrin receptor. J Med Microbiol 2020; 69: 457–464.

68.

Fazeli

Alebouyeh

Rezaei Tavirani

, et al. Helicobacter pylori CagA induced interleukin-8 secretion in gastric epithelial cells. Gastroenterol Hepatol Bed Bench 2016; 9(Suppl. 1): S42–S46.

69.

Crabtree

Taylor

Wyatt

, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 1991; 338: 332–335.

70.

Valmaseda Pérez

Gisbert

Pajares García

. Geographic differences and the role of cagA gene in gastroduodenal diseases associated with Helicobacter pylori infection. Rev Esp Enferm Dig 2001; 93: 471–480.

71.

Sozzi

Valentini

Figura

, et al. Atrophic gastritis and intestinal metaplasia in Helicobacter pylori infection: the role of CagA status. Am J Gastroenterol 1998; 93: 375–379.

72.

Kuipers

Pérez-Pérez

Meuwissen

, et al. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 1995; 87: 1777–1780.

73.

Zentilin

Reglioni

Savarino

. Pathophysiological characteristics of long- and short-segment Barrett’s oesophagus. Scand J Gastroenterol Suppl 2003: 40–43.

74.

Nandurkar

Talley

NJ.

Barrett’s esophagus: the long and the short of it. Am J Gastroenterol 1999; 94: 30–40.

75.

Talebi Bezmin Abadi

. Diagnosis of helicobacter pylori using invasive and noninvasive approaches. J Pathog 2018; 2018: 9064952.

76.

Nowak

JA.

Limitation of histology for detecting Helicobacter pylori. Gastrointest Endosc 1995; 41: 175–177.

77.

Shaheen

Falk

Iyer

, et al. ACG clinical guideline: diagnosis and management of Barrett’s Esophagus. Am J Gastroenterol 2016; 111: 30–50; quiz 1.

78.

The Chinese consensus for screening, diagnosis and management of Barrett’s esophagus and early adenocarcinoma (2017, Wanning). Zhonghua Nei Ke Za Zhi 2017; 56: 701–711.

79.

Xie

Zhang

Zheng

, et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. World J Gastroenterol 2013; 19: 6098–6107.

80.

Weston

Badr

Topalovski

, et al. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett’s esophagus, Barrett’s dysplasia, and Barrett’s adenocarcinoma. Am J Gastroenterol 2000; 95: 387–394.

81.

Ness-Jensen

Langhammer

Hveem

, et al. Helicobacter pylori in relation to asthma and allergy modified by abdominal obesity: the HUNT study in Norway. World Allergy Organ J 2019; 12: 100035.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.49 MB